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Summary Four cell lines of human (CCRF CEM and U266BL) or murine (L1210 and P388D1) origin,
resistant to the anthracycline antibiotic Adriamycin (doxorubicin) were selected in vitro from cultured cells by
serial passage in the presence of Adriamycin. The resistant sublines were also cross-resistant to Mitoxantrone,
4'-epi Adriamycin and a number of novel anthracyclines including 4'-deoxy and 4'-mpthoxy analogues.
However, a series of 9-alkyl substituted 4-demethoxyanthracyclines retained full activity against all the
resistant sublines as did Aclacinomycin A. These results suggest that 9-alkyl substitution of 4-demethoxy-
anthracyclines is an important determinant of activity against Adriamycin-resistant cell lines in vitro.
Adriamycin (doxorubicin, ADM) is currently used
as an effective chemotherapeutic agent, usually in
combination with other cytotoxic drugs, for the
treatment of leukaemia and a wide range of solid
tumours (Blum & Carter, 1974; O'Bryan, 1973).
However, the clinical efficacy of ADM is limited by
the emergence of drug resistance, resulting in
significant treatment failure (Selby, 1984).
Resistance to ADM in vitro can be induced in
tumour cell lines by cultivation in the presence of
drug (Biedler & Riehm, 1970; Dan0, 1973). In such
cultures, which have been used to investigate
resistance to anthracycline antibiotics in vitro, high
levels of resistance can be achieved; for example
P388 murine leukaemia can be rendered between 27
and 800 times more resistant to ADM than the
parental, sensitive line (Inaba & Johnson, 1978).
Generation of these 'super-resistant' cells has been
criticised because very high concentrations of ADM
are needed for their selection (Whelan & Hill,
1983). In practice, it would appear to be more
realistic to use pharmacologically achievable drug
levels, thus mimicking concentrations to which
cancers such as leukaemias are actually exposed.
It has been suggested that resistance to ADM
may be due to one or a combination of
mechanisms, including decreased cellular accumu-
lation, enhanced efflux of drug, reduced binding to
cell membranes and nuclei and variations in intra-
cellular enzyme levels (Kaye, 1985). Consequently
various strategies have been used in an attempt to
circumvent cellular resistance. N-acetyl daunomycin,
in combination with daunomycin, has been found
competitively to inhibit anthracycline efflux, thus
increasing the effective intracellular concentration
of daunomycin (Skovsgaard, 1980). There have
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also been claims that acquired resistance can be
overcome using calmodulin antagonists or agents
which block calcium influx (Kessel & Wilberding,
1984).
An alternative strategy has been to evaluate
structural analogues and so identify compounds
which retain activity against ADM-resistant cell
lines (Hill, 1985). Following the observations of
Twentyman et al. (1986) that the 9-methyl
anthracycline Ro 31-1215 was effective against
certain ADM-resistant lines, we have examined a
series of related 9-alkyl compounds using human
and murine cell lines rendered resistant to ADM.
Materials and methods
Drugs
Adriamycin (ADM) was obtained from Sigma. All
novel anthracyclines were synthesised in our
laboratories. 4'-epi ADM and Mitoxantrone were
generous gifts from Farmitalia and American
Cyanamid respectively. Aclacinomycin A was
obtained from Roche Nippon (Japan). Structures of
compounds are shown in Figure 1.
Drugs were dissolved at 1 mgml- in glass
distilled de-ionised water (Millipore, Milli-Q) with
the addition of up to 10% dimethyl sulphoxide
(DMSO). Small aliquots were stored at -200C
for up to 9 months, during which time no
decomposition was detectable by HPLC.
Cell culture
Four cell lines, two human and two murine, were
selected for investigation. CCRF CEM and U266BL
are human lymphoblastoid leukaemia lines of
T- and B-cell paternity, respectively. U266BL
was obtained from Dr H.J. Field (Cambridge).
CCRF CEM and the two murine lines L1210 and
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P388D1 were obtained from Flow Laboratories. All
cell lines were maintained as suspension cultures
in RPMI 1640 plus 25 mm HEPES and 2mM
L-glutamine with the addition of 10% (v/v) foetal
calf serum (FCS). All media and additives were
obtained from Gibco. No antibiotics were used.
Cultures were incubated at 37°C in a humidified
atmosphere of 5% CO2 +95% air. All cultures
were periodically checked for mycoplasma infection.
Derivation ofADM-resistant sublines
To select for ADM resistance, cultures were exposed
to progressively increasing concentrations of ADM
in the culture medium. The overall procedure was
consistent for all cell lines, although exact details
vary as described.
General method A semi confluent culture was
initially exposed to 0.01 gml-1 ADM (half the
IC50 obtained for CCRFCEM cells, the most
susceptible cell line). The cultures were then
incubated undisturbed until such time as a
confluency had been reached (1-3xlO16cellsml 1),
when a further dose of ADM was given. Between
each increment, the culture was resuspended in 5ml
fresh medium and diluted to approximately
8 x 104cellsml-I in drug-containing medium. A
portion of each culture was retained at each
progression. As expected, the incubation interval
lengthened with increasing concentration of ADM,
although once the resistance subline was finally
established the doubling time was similar to that of
the parental line. Prior to experimental use, cells
were cultivated for seven days in drug-free medium.
Thus, each of the four cell lines had slightly
different derivations because of (i) the time required
for culture adaptation and (ii) the number of
exposures to each concentration of ADM required
before an increase was possible. ADM concen-
tration was increased to a maximum of 0.5 ugml-I
or until the time required to achieve confluency was
in excess of 14 days.
U266BL The initial dose of 0.01 ugml 1 was
repeated twice with seven days incubation on each
occasion. The triple exposure procedure was
repeated with escalating doses of ADM from 0.02
to 0.5pgml-1. It was not necessary to have a drug-
free interval between each dose of ADM as the cells
recovered quickly at each stage. The resistant
subline thus generated was designated U266BL/
ADM.
CCRFCEM ADM (0.01 gml 1) was added to
the culture twice weekly for 8 weeks. Any attempt
to increase the ADM concentration during this
period resulted in destruction of the culture.
Graded concentrations of ADM from 0.02 to
0.2pgml-1 were used with long exposure times at
each concentration and with 10 days cultivation in
the absence of drug between each dose. It was
found that 0.2pgml-1 was the highest concentration
of ADM to which these cells could be subjected
without lengthy recovery at each dose. The subline
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L1210 ADM (0.01 ygml-1) was added to the
cultures twice weekly for three weeks with 10 days
growth in drug-free medium between each week of
exposure. The concentration of ADM was increased
to 0.02 Mgml-1 twice weekly for six weeks with 7
days drug-free culture between each week of
exposure. All attempts to increase the ADM
concentration to 0.025Mgml-1 failed. Selected cells
that formed the final culture were more resistant to
ADM than had been expected, possibly because the
culture was examined expertimentally after cryo-
preservation. The resistant subline was designated
L1210/ADM.
P388D1 Cultures wre exposed to continuous
escalating concentrations of ADM from 0.01 to
0.1 gml-1 over a 12-week period, followed by
0.2pgml-1 twice weekly for 6 weeks. All attempts
at further dose increase resulted in culture death.
Cultivation in drug-free medium between each
escalating dose was not necessary with this line.
The resistant subline was designated P388D1/ADM.
Anti-proliferation assay
Stock solutions of drug were diluted to the required
concentration in tissue culture medium. Growth
medium was added to each well of a 24-well Nunc
plate, followed by the appropriate volume of
diluted drug to a total of 2ml. Each dilution was
tested in either duplicate or triplicate. DMSO
concentration was below 0.1% (v/v) and did not
affect cell proliferation. Prepared plates were
equilibrated in the CO2 incubator for up to 3h to
reduce cell growth lag after inoculation. Cultures
were harvested by centrifugation at 200g for 6-7
minutes. Cell pellets were resuspended in 10-20ml
fresh medium; these cells remained fully viable, by
Trypan blue exclusion, for 3 h in the CO2
incubator. Ten to twenty microlitres of the
suspension were diluted to give 1-5 x 104cellsml-1
in each well. Inoculated plates were incubated for
three to four days at 37'C in a humidified
atmosphere of 5% CO2 and 95% air. Drug-free
controls had reached confluency in this time at
between 1-3 x 106cellsml-1. The population
doubling time of all strains was approximately 13 h.
The 50% inhibitory concentration (IC50) was
interpolated from a semi-log plot of each drug
concentration against cell growth expressed as a
percentage of that observed in the drug-free
controls. Cell growth was defined as the total
number of cellsml-1 at the end of the incubation
period as determined using model ZM Coulter
counter. Under the conditions described these
cultures were 90-95% viable determined by Trypan
blue dye exclusion.
Results
Anti-proliferative activity ofanthracyclines against
the parental, sensitive cell lines
The relative cytotoxicity of the 9-alkyl anthra-
cyclines and four reference compounds against
the four parental cell lines is shown in Table I.
ADM was equally potent against CCRFCEM,
U266BL and L1210, with P388D1 somewhat less
sensitive. The spectrum of activity of the 4'-epi
analogue varied slightly with CCRFCEM, L1210
and P388D1 equally susceptible, but with U266BL
considerably more sensitive to this compound.
Aclacinomycin A was not tested against L1210;
activity varied against other cell lines. The two 9-
ethyl compounds, Ro 31-1749 and Ro 31-1966 were
more active than the 9-methyl analogues in all lines
tested. The activity of the 9-methyl compounds Ro
31-1215 and Ro 31-1740 approximated to that of
ADM in each cell line.
In these four cell lines the novel 9-alkyl
analogues and Mitoxantrone had a greater overall
activity in comparison to ADM; 4'-epi ADM had
similar efficacy whereas Aclacinomycin A was the
only compound with consistently lower activity.
Cross resistance with novel antracyclines
The IC50 values and calculated degrees of resistance
for the two human and murine lines are
summarised in Tables II and III respectively. The
degree of resistance to ADM itself varied from line
to line. P388D1/ADM was most resistant, with a
resistance factor (RF) of 14. U266BL/ADM had an
RF of nearly 10, CCRFCEM/ADM of almost 6
and L1210/ADM an RF of 4.5. The other
compounds used as standards, 4'-epi ADM and
Mitoxantrone, also had varying degrees of
resistance. The RF obtained for 4'-epi ADM
against P388D1 was 13, for U266BL was 11 and
for CCRF CEM was 4, but an RF of only 3 was
obtained against L1210. Mitoxantrone on the other
hand had a different pattern of resistance.
P388D1/ADM was the most resistant (RF =55)
whilst CCRF CEM had an RF of 14, U266BL an
RF of -6 and L1210 an RF of 3.
In contrast to the 9-alkyl derivatives, the 9-
hydroxyalkyl compound, Ro 31-1741 and the
secondary urethane, Ro 31-2035 were cross-
resistant in all the cell lines tested. It is possible
that the RF of 2.5 in U266BL indicates only partial
cross-resistance. This phenomenon was also seen
for a 4'-methoxy (Ro 31-2175) and 4'-deoxy (Ro
31-2118) analogue, for which the RFs obtained
were between 2 and 4. A series of novel 9-alkyl
compounds was also examined using Aclacinomycin
A as a reference compound as this also has a 9-
alkyl substitution. In all cases, with the 9-methyl, 9-598 C.A. SCOTT et al.
Table I Growth inhibitory effect of 9-alkyl anthracyclines and reference
compounds on four mammalian cell lines
Mean ICso (pgml1)a
CCRF CEM U266BL P388D1 L1210
Adriamycin 0.019 0.029 0.056 0.020
4'-epi-adriamycin 0.013 0.004 0.096 0.012
Mitoxantrone 0.003 0.006 0.038 0.002
Aclacinomycin A 0.026 0.097 0.180
31-1215 0.014 0.024 0.034 0.027
31-1740 0.010 0.062 0.240
31-1749 0.005 0.009 0.030
31-1966 0.006 0.013 0.034 -
aMeans calculated from between 2 and 6 experiments, each in duplicate or
triplicate.
Table II Activity ofanthracyclines in ADM-resistant and sensitive human cell lines
ICso (pgml 1) IC50 (bgml )a
Resistance Resistance
Compound CCRF CEM CCRF CEM/ADM factorb U266BL U266BL/ADM factorb
ADM 0.019 0.109 5.74 0.029 0.230 9.30
4'-epi-ADM 0.013 0.050 3.85 0.004 0.044 11.00
Mitoxantrone 0.003 0.042 14.00 0.006 0.034 5.67
Aclacin. A 0.026 0.030 1.15 0.097 0.112 1.15
31-1215 0.014 0.020 1.42 0.024 0.030 1.25
31-1740 0.01 0.018 1.80 0.062 0.069 1.11
31-1749 0.005 0.005 1.00 0.009 0.011 1.22
31-1966 0.006 0.007 1.17 0.013 0.012 0.92
31-1741 0.006 0.050 8.33 0.004 0.031 7.75
31-2035 0.042 0.218 5.19 0.170 0.428 2.52
31-2175 0.002 0.006 3.00
31-2118 0.002 0.005 2.50 - -
aMeans calculated from between 2 and 6 experiments, each in duplicate ot triplicate; bResistance
Factor RF=IC50 (pgml-1) resistance subline/IC50 (jugml-1) sensitive subline.
Table III Activity ofanthracyclines on ADM-resistant and sensitive murine cell lines
IC50 (gml l)a IC50 (igml l)a
Resistance Resistance
Compound P388D1 P388D1/ADM factorb L1210 L1210/ADM factorb
ADM 0.056 1.210 14.07 0.020 0.090 4.50
4'-epi-ADM 0.096 1.230 12.81 0.012 0.040 3.30
Mitoxantrone 0.038 2.100 55.26 0.002 0.006 3.00
Aclacin. A 0.180 0.260 1.44
31-1215 0.034 0.032 0.94 0.027 0.210 0.78
31-1740 0.240 0.320 1.33
31-1749 0.030 0.022 0.73
31-1966 0.034 0.028 0.82
31-1741 0.005 0.074 14.80 0.003 0.023 7.67
31-2035 0.250 7.500 30.00 0.116 0.650 5.60
31-2175 0.004 0.016 4.00
31-2118 0.006 0.023 3.83
aMeans calculated from between 2 and 6 experiments, each in duplicate or triplicate; bResistance
Factor RF=IC50 (pgml-1) resistance subline/1C50 (gmln-1) sensitive subline.9-ALKYL ANTHRACYCLINES AND CROSS-RESISTANCE 599
ethyl and reference compound, a lack of cross-
resistance was demonstrated in ADM-resistant cells.
Discussion
The observations indicate that 9-alkyl substitution
of 4-demethoxyanthracyclines is more important in
determining activity against ADM-resistant CCRF
CEM, U266BL, L1210 and P388D1 cells in vitro,
than modifications to the sugar moiety.
The resistant human and murine cell lines
described in this paper showed a modest degree of
resistance to ADM, probably because of the low
levels of drug to which they were exposed in vitro.
However, this may be considered to approximate to
the degree of resistance which occurs clinically.
Whilst no specific analysis was made of the
stability of the cell populations, examination of
IC50s subsequent to these studies did suggest a slow
decline, possibly indicating that the mutation was
unstable or alternatively that a sensitive population
had overgrown the resistant subline. The latter
explanation is less likely since the doubling times of
sensitive and resistant strains of each cell line were
similar (approximately 13h). However, since it was
our intention to mimic, at least to some extent, the
events that occur clinically, it was felt that clonal
selection of each population was not required.
The U266BL and P388D1 resistant sublines were
selected using continuous escalating doses of drug
while selection ofresistant sublines from CCRF CEM
and L1210 required intervals of drug-free culture
to facilitate cell recovery. The different modes of
derivation did not seem to affect the degree of
resistance obtained, although L1210/ADM which
was exposed to the lowest concentrations of ADM,
showed a lesser degree of resistance than other
sublines. However, there appeared to be more
correlation betwen the IC50 value for the resistant
lines and the highest concentration of ADM to
which they had been exposed during selection.
It is only recently that modifications of drug
structure have been reported to be of use in
overcoming anthracycline resistance. Whilst other
anthracyclines containing deoxy- and methoxy-
sugars have been found by others not to be cross-
resistant with ADM (Hill, 1985), we have shown
that Ro 31-2118 and Ro 31-2175 were 2.5 to 4
times less active in the resistant cell line than in the
parental culture. In contrast, the four 9-alkyl
anthracyclines were equally effective against all
ADM sensitive and resistant cell lines irrespective
of the configuration of the 4'-hydroxyl group of the
sugar. This lack of cross-resistance was not due to
the absence of the 4-methoxy group since all the
other novel compounds tested were less active
against resistant cultures. The significance of the 9-
alkyl substitution was also highlighted by the lack
of cross-resistance of Aclacinomycin A with ADM.
Furthermore, the 9-ethyl derivatives were
consistently more active than the 9-methyl
compounds, possibly due to the lipophilic nature of
the substitution; although Aclacinomycin A which
also has a 9-ethyl substituent is of similar
lipophilicity to Ro 31-1215 (Twentyman et al.,
1986).
Current chemotherapy could benefit from new
approaches to treatment methods; it has been
suggested that circumvention of drug-resistance
may be of importance (Selby, 1984). Maral et. al.
(1983) have reported the apparent absence of cross-
resistance between ADM and Aclacinomycin A in
patients with acute myoblastic leukaemia. The
results with the 9-alkyl anthracyclines presented in
this paper also indicate a possible method for
overcoming anthracycline resistance. This study and
the observation of Maral et al. together with the
potency demonstrated by our 9-alkyl analogues in
animal models (unpublished) suggest that these
compounds warrant clinical evaluation. Further
chemical exploration of 9-substituted anthracyclines
would also appear to be fully justified.
The authors are indebted to Dr J.A. Martin for his
helpful suggestions throughout the course of this study as
well as to Miss M. Fawcett and Mrs S.A. Morrissey for
their excellent secretarial support.
References
BIEDLER, J.L. & RIEHM, H. (1970). Cellular resistance to
actinomycin D in Chinese hamster cells. Cancer Res.,
30, 1174.
BLUM, R.H. & CARTER, S.K. (1974). Adriamycin. A new
anticancer drug with significant clinical activity. Ann.
Intern. Med., 80, 249.
DAN0, K. (1973). Active outward transport of
daunomycin in resistant Ehrlich ascites tumour cells.
Biochim. Biophys. Acta 323, 466.
HILL, B.T. (1985). Identification of anthracycline
analogues with enhanced toxicity and lack of cross-
resistance of ADM using a series of mammalian cell
lines in vitro. Cancer Chemother. Pharmacol., 14, 194.
INABA, M. & JOHNSON, K.K. (1978). Uptake and
retention of adriamycin and daunorubicin by sensitive
and anthracycline resistant sublines of P388 leukaemia.
Biochem. Pharmacol., 27, 2123.600 C.A. SCOTT et al.
KAYE, S. (1985). Tumour cell resistance to anthracyclines
- a review. Cancer Chemother. Pharmacol., 14, 96.
KESSEL, D. & WILBERDING, C. (1984). Mode of calcium
antagonists which alter anthracycline resistance.
Biochem. Pharmacol., 33, 1157.
MARAL, R., BOURUT, C., CHENU, E. & 1 other (1983). In
Current Drugs and Methods of Cancer Treatment,
Mathe, G. (ed) p. 189. Masson Publishing Inc. USA.
O'BRYAN, R.M., LUCE, J.K., TALLEY, R.W. & 2 others
(1973). Phase II evaluation of ADM in human
neoplasia. Cancer, 32, 1.
SELBY, P. (1984). Acquired resistance to cancer chemo-
therapy. Br. Med. J., 288, 1252.
SKOVSGAARD, T. (1980). Circumvention of resistance to
daunorubicin by N-acetyl daunorubicin in Ehrlich
ascites tumour cells. Cancer Res., 40, 1077.
TWENTYMAN, P.R., FOX, N.E., WRIGHT, K.A. & 2 others
(1986). The in vitro effects and cross-resistance patterns
of some novel anthracyclines. Br. J. Cancer, 53 (this
issue).
WHELAN, R.D.H. & HILL, B.T. (1983). Patterns of drug
sensitivity in human breast tumour line (MCF-7) and
the development of resistance. In Imperial Cancer
Research Fund Ann. Rept. p. 148.